Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/4708
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nyakato, Patience | - |
dc.contributor.author | Schomaker, Michael | - |
dc.contributor.author | Sipambo, Nosisa | - |
dc.contributor.author | Technau, Karl-Günter | - |
dc.contributor.author | Fatti, Geoffrey | - |
dc.contributor.author | Rabie, Helena | - |
dc.contributor.author | Tanser, Frank | - |
dc.contributor.author | Eley, Brian | - |
dc.contributor.author | Euvrard, Jonathan | - |
dc.contributor.author | Wood, Robin | - |
dc.contributor.author | Tsondai, Priscilla R. | - |
dc.contributor.author | Yiannoutsos, Constantin T. | - |
dc.contributor.author | Cornell, Morna | - |
dc.contributor.author | Davies, Mary-Ann | - |
dc.date.accessioned | 2021-06-28T08:28:55Z | - |
dc.date.available | 2021-06-28T08:28:55Z | - |
dc.date.issued | 2020 | - |
dc.identifier.uri | https://journals.lww.com/aidsonline/Abstract/2021/05010/Virologic_response_of_adolescents_living_with.13.aspx | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4708 | - |
dc.description.abstract | Background and objectives: Adolescents living with perinatally acquired HIV (ALPHIV) on antiretroviral therapy (ART) have been noted to have poorer adherence, retention and virologic control compared to adolescents with non-perinatally acquired HIV, children or adults. We aimed to describe and examine factors associated with longitudinal virologic response during early adolescence. Design: A retrospective cohort study Methods: We included ALPHIV who initiated ART before age 9.5 years in South African cohorts of the International epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) collaboration (2004–2016); with viral load (VL) values <400 copies/ml at age 10 years and at least one VL measurement after age 10 years. We used a log-linear quantile mixed model to assess factors associated with elevated (75th quantile) VLs. Results: We included 4396 ALPHIV, 50.7% were male, with median (interquartile range) age at ART start of 6.5 (4.5, 8.1) years. Of these, 74.9% were on a non-nucleoside reverse transcriptase inhibitor (NNRTI) at age 10 years. After adjusting for other patient characteristics, the 75th quantile VLs increased with increasing age being 3.13-fold (95% CI 2.66, 3.68) higher at age 14 versus age 10, were 3.25-fold (95% CI 2.81, 3.75) higher for patients on second-line protease-inhibitor and 1.81-fold for second-line NNRTI-based regimens (versus first-line NNRTI-based regimens). There was no difference by sex. Conclusions: As adolescents age between 10 and 14 years, they are increasingly likely to experience higher VL values, particularly if receiving second-line protease inhibitor or NNRTI-based regimens, which warrant adherence support interventions. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolters Kluwer Health, Inc | en_US |
dc.subject | Antiretroviral therapy | en_US |
dc.subject | Early adolescence | en_US |
dc.subject | HIV | en_US |
dc.subject | Perinatal infection | en_US |
dc.subject | Virologic response | en_US |
dc.title | Virologic response of adolescents living with perinatally acquired HIV receiving antiretroviral therapy in the period of early adolescence (10–14 years) in South Africa | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.